drugset / Trial / NCT01381445

A Study Assessing GW870086's Potential to Cause Skin Thinning

NCT01381445

Phase 1 Completed 20 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindOther

Summary

This study is a randomised, double-blind, placebo-controlled study of topical GW870086 to explore the potential for skin thinning in healthy adult volunteers after 42±2 days of treatment. Twenty (20) healthy volunteers will be randomised to receive placebo and GW870086 2% cream, they will also receive either of the following treatments: GW870086 0.2% cream, or clobetasol propionate 0.05% cream.

Timeline

Start
2011-04-14
Primary completion
2011-07-07
Completion
2011-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject GW870086 Small molecule 0.2 % Topical
Subject GW870086 Small molecule 2 % Topical
Subject clobetasol propionate Small molecule 0.05 % Topical

Indications